Interpreting recent clinical studies for COVID-19: A continual process with more new data - 08/02/22
Doi : 10.1016/j.accpm.2021.101016
Jean M. Connors a, Matthew Moll b, Jerrold H. Levy c, ⁎ 
a Hematology Division, Department of Medicine, Hematology Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
b Channing Division of Network Medicine and Division of Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
c Departments of Anesthesiology, Critical Care, and Surgery, Duke University School of Medicine, Durham, NC, USA
⁎Corresponding author at: Duke University Medical Center, 2301 Erwin Rd., 5691H HAFS Box 3094, Durham, NC 27710, USA.Duke University Medical Center2301 Erwin Rd.5691H HAFS Box 3094DurhamNC27710USA
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.
Conéctese para beneficiarse!
Keywords : Anticoagulation, Clinical trials, COVID-19, Heparin, Hypercoagulability, Resistance, Thrombosis
El texto completo de este artículo está disponible en PDF.
Esquema
© 2021
Société française d'anesthésie et de réanimation (Sfar). Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Vol 41 - N° 1
Artículo 101016- février 2022 Regresar al número
Artículo precedente
- Extracorporeal membrane oxygenation for COVID-19: Some answers and a remaining question
- Florent Laverdure, Benjamin Frossard, Clément Monet, Julien Amour
- Selective digestive decontamination and COVID-19: Uncertainty in a moving area
- Marc Leone, Ines Lakbar, Alexandre Lopez, Claire Zunino, Ignacio Martin Loeches
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.